All articles
Can Mounjaro® Cause Depression: Causes and Prevention
Reading time:
5 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
Depression Incidence: Mounjaro® Compared with Other GLP-1 Meds
When comparing Mounjaro® to other GLP-1 receptor agonists, it's crucial to consider:
Similar side effect profiles: Depression as a side effect is not unique to Mounjaro® but is a concern with other medications in this class (2).
A recent analysis from the World Health Organization global database found a possible link between those taking the GLP-1 medication semaglutide (main ingredient in Ozempic® and Wegovy) and increased suicidal thoughts, particularly among those already on antidepressants. (5) The FDA cautions those on Wegovy® to monitor for symptoms of depression or suicidal thoughts while on the medication. (6)
Individual variability: Some users may react differently to different medications, with some experiencing fewer mood-related side effects on Mounjaro® than other GLP-1 meds.
Learn more about other GLP-1 medications here.
In conclusion, while the connection between Mounjaro® and depression is still under investigation, being informed and vigilant about potential symptoms can empower users to manage their health proactively. Always consult with healthcare professionals for personalized advice and support.
Get Tailored Support From Mochi Health
Remember, you're not alone in navigating these challenges. It’s important to receive personalized support and guidance on your journey. At Mochi Health, compassionate providers and dietitians are available to help you get lasting results, manage symptoms, and improve your quality of life.
If you want to get started on Mounjaro® or need more guidance on managing your overall health on weight loss medications, consider Mochi Health as your comprehensive solution. Find out if you are eligible for our program today.
References:
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine, 387(3), 205–216. https://www.nejm.org/doi/10.1056/NEJMoa2206038?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Arillotta, D., Floresta, G., Guirguis, A., Corkery, J. M., Catalani, V., Martinotti, G., Sensi, S. L., & Schifano, F. (2023). GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain sciences, 13(11), 1503. https://doi.org/10.3390/brainsci13111503
“MOUNJAROTM (Tirzepatide) Injection, for Subcutaneous Use.” Access Data FDA, Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
Anna Miller, RN, et al. “Most GLP-1 Medications Correlated with a Lower Likelihood of Anxiety and Depression Diagnoses.” Epic Research. https://www.epicresearch.org/articles/most-glp-1-medications-correlated-with-a-lower-likelihood-of-anxiety-and-depression-diagnoses
Schoretsanitis G, Weiler S, Barbui C, Raschi E, Gastaldon C. Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality. JAMA Netw Open. 2024;7(8):e2423385. doi:10.1001/jamanetworkopen.2024.23385. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2822453?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamanetworkopen.2024.23335&utm_source=BulletinHealthCare&utm_medium=email&utm_term=082124&utm_content=MEMBER&utm_campaign=article_alert-morning_rounds_daily&utm_uid=15689092&utm_effort=MRNRD0#google_vignette
Food and Drug Administration. (n.d.). Wegovy® (semaglutide) injection, for subcutaneous use. Access Data FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles















